An interventional study of High-Frequency, ipsilateral M1 and High-Frequency, bilateral M1 in Parkinson's Disease and Parkinsonism, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.
Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is the 33rd largest by planned enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2024, is one of 28 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 64th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Innopeutics Corporation · Sites in Korea, Republic of
Ages 50–80
Innopeutics Corporation · Sites in Korea, Republic of
Ages 50–80
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Australia and 14 more countries
Ages 50–85
Pusan National University Yangsan Hospital · Sites in Korea, Republic of
Ages 40+
Kliniken Beelitz GmbH · Sites in Korea, Republic of, Austria, Germany and 5 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 9 · Phase 4 16
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 60 across the 67 interventional studies, 500 across the 9 observational. Of the 45 that completed or were terminated, 12 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 76 have an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Parkinson Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07569133Ho-Won LeeEfficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease | 2026-11-27 |
| NCT07522138Seoul National University HospitalHome-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study | 2026-12-01 |
| NCT01799915NYU Langone HealthNatural History Study of Synucleinopathies | 2026-12-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.
rTMS treatment for patients with Parkinson's disease is traditionally based on stimulating the neural network of brain. The widely-used traditional rTMS treatment protocol involves high-frequency stimulation over the bilateral primary motor cortex (M1) to enhance motor and gait functions. However, concerns have arisen regarding the effect of rTMS on motor recovery in patients with Parkinson's disease. Although still subject to debate, a possible reason for the diverse results of rTMS applied is the uniform application protocol to individuals with varying pathologies and functional reserves, aimed at enhancing recovery.
Therefore, this study was aimed to determine the effects of protocols of rTMS therapy based on the functional reserve of each patient with Parkinson's disease.
Based on screening evaluations (Timed Up and Go Test (TUG), Timed Up and Go Dual Task-Cognitive (TUG-Cog)), investigators hypothesized that patients could be categorized into two groups: 1) priority in motor functional reserve, 2) priority in cognitive functional reserve. For each group, investigators plan to randomly assign patients to experimental and control groups to demonstrate the efficacy of different rTMS protocols based on functional reserves compared to conventional high-frequency rTMS applied to the bilateral M1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with motor priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over more affected primary motor cortex (M1) of lower extremity will be applied.
Device: High-Frequency, ipsilateral M1
Patients with motor priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied.
Device: High-Frequency, bilateral M1
Patients with cognitive priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over Lt. dorsolateral prefrontal cortex (DLPFC) will be applied.
Device: High-Frequency, Lt. DLPFC
Patients with cognitive priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied.
Device: High-Frequency, bilateral M1
rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: ipsilateral primary motor cortex of lower extremity. Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.
rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: bilateral primary motor cortex of lower extremity. Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.
rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: Lt. DLPFC Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.
rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: bilateral primary motor cortex of lower extremity. Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.
Differences of Timed Up and Go Test (TUG)
Measurement for gait function.
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Timed Up and Go Test (TUG)
Measurement for gait function.
Time frame: From baseline T0 to During-intervention T1 (2 weeks)
Differences of Timed Up and Go Test (TUG)
Measurement for gait function.
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Timed Up and Go Test-Cognitive (TUG-Cog)
Measurement for gait and cognitive function.
Time frame: From baseline T0 to During-intervention T1 (2 weeks)
Differences of Timed Up and Go Test-Cognitive (TUG-Cog)
Measurement for gait and cognitive function.
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Timed Up and Go Test-Cognitive (TUG-Cog)
Measurement for gait and cognitive function.
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III
Measurement for motor function of patients with Parkinson's disease. Score ranges from 0 to 132; higher score indicates more severity of disease status
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of MDS-UPDRS, Part III
Measurement for motor function of patients with Parkinson's disease. Score ranges from 0 to 132; higher score indicates more severity of disease status
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of New Freezing of Gait Questionnaire (FoG-Q)
Measurement for gait function of patients with Parkinson's disease Score ranges from 0 to 28; higher score indicates more severity of disease status
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of New Freezing of Gait Questionnaire (FoG-Q)
Measurement for gait function of patients with Parkinson's disease Score ranges from 0 to 28; higher score indicates more severity of disease status
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Digit span Test
Measurement for cognitive function
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Digit span Test
Measurement for cognitive function
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Trail making Test
Measurement for cognitive function
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Trail making Test
Measurement for cognitive function
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Gait speed)
Measurement for gait function. Gait speed (km/hr) will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Gait speed)
Measurement for gait function. unit: km/hr Gait speed (km/hr) will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Stride length)
Measurement for gait function Stride length (m) will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Stride length)
Measurement for gait function Stride length (m) will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Step count)
Measurement for gait function Step count will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Step count)
Measurement for gait function Step count will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Cadence)
Measurement for gait function Cadence (step count/min) will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Cadence)
Measurement for gait function Cadence (step count/min) will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Swing ratio)
Measurement for gait function Swing ratio (% of swing phase of 1 gait cycle) will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Swing ratio)
Measurement for gait function Swing ratio (% of swing phase of 1 gait cycle) will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Stride time)
Measurement for gait function Stride time (unit- second, time from heel strike to next heel strike) will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Stride time)
Measurement for gait function Stride time (unit- second, time from heel strike to next heel strike) will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Differences of Gait lab parameter (Pressure distribution)
Measurement for gait function Pressure distribution (unit - pecentage, pressure distribution among heel, mild, and toe) will be measured
Time frame: From baseline T0 to Post-intervention T2 (4 weeks)
Differences of Gait lab parameter (Pressure distribution)
Measurement for gait function Pressure distribution (unit - pecentage, pressure distribution among heel, mild, and toe) will be measured
Time frame: From baseline T0 to Follow-up T3 (2 months)
Plan to share: No
Started Feb 2024 (actual). Primary completion is estimated for Sep 2026, 31 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 31 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.